China has witnessed a bullish growth in biotech, with a plethora of labs and biopharmas churning out innovative healthcare solutions. In 2020, Chinese healthcare startups raised $29.3 billion, almost double the 2019 funds. What factors spur the growth of biotech in China? How can companies map a strategy for tapping into the country’s growth and innovation in biotech? How will China’s biotech reshape the global biopharma landscape? What are the opportunities and continuing challenges? And how does US-China tension influence affect the outlook for collaboration?